Related Experiment Videos
[Development of drugs to overcome drug resistance--basic approaches]
1Institute of Molecular and Cellular Biosciences, University of Tokyo.
Abstract:
P-glycoprotein plays a key role in the mechanisms of multidrug resistance in experimental tumors as well as in clinical tumors both in acquired and intrinsic-type resistance. Thus the therapeutic approaches targeting P-glycoprotein would provide benefits in eradication of drug-resistant tumor cells, although some potential problems concerning side effects still remain to be studied. Practical approaches to overcoming multidrug resistance by targeting the P-glycoprotein would be (1) to use antibodies against P-glycoprotein; and (2) to use agents, including calcium channel blocker-related agents and membrane-modifying agents, that interact with P-glycoprotein. These therapeutic approaches will be discussed in the symposium.
Insights
Targeting P-glycoprotein can overcome multidrug resistance in tumors. Strategies include using antibodies or agents like calcium channel blockers to enhance cancer therapy efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- P-glycoprotein is crucial in multidrug resistance (MDR) in both experimental and clinical tumors.
- This resistance can be intrinsic or acquired, significantly hindering cancer treatment effectiveness.
Purpose of the Study:
- To explore therapeutic strategies targeting P-glycoprotein to overcome MDR.
- To discuss the potential benefits and challenges of P-glycoprotein-targeted therapies.
Main Methods:
- Review of existing research on P-glycoprotein's role in MDR.
- Identification and discussion of two primary approaches: antibody-based therapy and MDR modulator agents.
- Consideration of calcium channel blocker-related agents and membrane-modifying agents.
Main Results:
- P-glycoprotein is a significant factor in tumor drug resistance.
- Targeting P-glycoprotein offers a promising avenue for eradicating drug-resistant cancer cells.
- Potential side effects of P-glycoprotein targeting require further investigation.
Conclusions:
- Therapeutic targeting of P-glycoprotein holds promise for improving cancer treatment outcomes.
- Antibodies and specific agents represent viable strategies to combat P-glycoprotein-mediated MDR.
- Further research is needed to address safety concerns and optimize these approaches.